Evidence mapPaperPMID 28828479Full record

ArticleJAMA internal medicine2017

Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use.

Andrew J Karter, E Margaret Warton, Kasia J Lipska, James D Ralston, Howard H Moffet, Geoffrey G Jackson, Elbert S Huang, Donald R Miller

3 registry-linked trialsOpen access · greenAbstract readMulticenter StudyValidation Study
In one paragraph

Article in JAMA internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 89 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07547878 phase4not yet recruitingstarted 2026, after this paper: background citation

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Ran2026Enrolled64Registered outcomes18Posted comparisons0ConditionsChronic Kidney Disease, Type 2 DiabetesArmsAccupril, Aceon, Altace, Atacand, Avapro
Open the trial in the graph
NCT04863872 nacompletednot on this mapstarted 2022, after this paper: background citation

Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia

TypeinterventionalSponsorKaiser PermanenteRan2022 to 2024Enrolled259ConditionsSevere HypoglycemiaArmsProactive Care Management, MyHC-T2D education program
NCT06746714 nacompletednot on this mapstarted 2023, after this paper: background citation

Testing a New Population Management Model for Hypoglycemia Prevention in High-Risk KPNC Members

TypeinterventionalSponsorKaiser PermanenteRan2023 to 2024Enrolled200ConditionsDiabetesArmsProactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia), Usual care, after system-side dissemination of HOAP
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Artificial Intelligence to Diagnose Complications of Diabetes.Journal of diabetes science and technology · 2025
    Review
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Andrew J KarterDivision of Research, Kaiser Permanente Northern California, Oakland.
E Margaret WartonDivision of Research, Kaiser Permanente Northern California, Oakland.
Kasia J LipskaSection of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
James D RalstonKaiser Permanente Washington Health Research Institute, Seattle.
Howard H MoffetDivision of Research, Kaiser Permanente Northern California, Oakland.
Geoffrey G JacksonKaiser Permanente Washington Health Research Institute, Seattle.
Elbert S HuangSection of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.
Donald R MillerCenter for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts.
Kaiser Permanente · USKaiser Permanente Washington Health Research Institute · USEdith Nourse Rogers Memorial Veterans Hospital · USUniversity of Chicago · USUniversity of Washington · USYale University · US

Funding

Yale Clinical and Translational Science AwardUL1TR001863 · YALE UNIVERSITY · 2025 to 2025
$9.9M
Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · KAISER FOUNDATION RESEARCH INSTITUTE · 2025 to 2025
$700k
Research Design, Data, and Analytics CoreP30DK092949 · UNIVERSITY OF CHICAGO · 2025 to 2025
$660k
NCATS NIH HHS UL1 TR001863NIA NIH HHS K23 AG048359NIDDK NIH HHS K24 DK105340NIDDK NIH HHS P30 DK092924NIDDK NIH HHS P30 DK092949NIDDK NIH HHS R01 DK081796NIDDK NIH HHS R01 DK103721
6 · The paper itself

Abstract

Importance: Hypoglycemia-related emergency department (ED) or hospital use among patients with type 2 diabetes (T2D) is clinically significant and possibly preventable. Objective: To develop and validate a tool to categorize risk of hypoglycemic-related utilization in patients with T2D. Design, Setting, and Participants: Using recursive partitioning with a split-sample design, we created a classification tree based on potential predictors of hypoglycemia-related ED or hospital use. The resulting model was transcribed into a tool for practical application and tested in 1 internal and 2 fully independent, external samples. Development and internal testing was conducted in a split sample of 206 435 patients with T2D from Kaiser Permanente Northern California (KPNC), an integrated health care system. The tool was externally tested in 1 335 966 Veterans Health Administration and 14 972 Group Health Cooperative patients with T2D. Exposures: Based on a literature review, we identified 156 candidate predictor variables (prebaseline exposures) using data collected from electronic medical records. Main Outcomes and Measures: Hypoglycemia-related ED or hospital use during 12 months of follow-up. Results: The derivation sample (n = 165 148) had a mean (SD) age of 63.9 (13.0) years and included 78 576 (47.6%) women. The crude annual rate of at least 1 hypoglycemia-related ED or hospital encounter in the KPNC derivation sample was 0.49%. The resulting hypoglycemia risk stratification tool required 6 patient-specific inputs: number of prior episodes of hypoglycemia-related utilization, insulin use, sulfonylurea use, prior year ED use, chronic kidney disease stage, and age. We categorized the predicted 12-month risk of any hypoglycemia-related utilization as high (>5%), intermediate (1%-5%), or low (<1%). In the internal validation sample, 2.0%, 10.7%, and 87.3% were categorized as high, intermediate, and low risk, respectively, with observed 12-month hypoglycemia-related utilization rates of 6.7%, 1.4%, and 0.2%, respectively. There was good discrimination in the internal validation KPNC sample (C statistic = 0.83) and both external validation samples (Veterans Health Administration: C statistic = 0.81; Group Health Cooperative: C statistic = 0.79). Conclusions and Relevance: This hypoglycemia risk stratification tool categorizes the 12-month risk of hypoglycemia-related utilization in patients with T2D using only 6 inputs. This tool could facilitate targeted population management interventions, potentially reducing hypoglycemia risk and improving patient safety and quality of life.

Indexed as

Quality of LifeDelivery of Health Care, IntegratedDiabetes Mellitus, Type 2Electronic Health RecordsEmergency Service, HospitalFemaleFollow-Up StudiesHumansHypoglycemiaHypoglycemic AgentsIncidenceMaleProspective StudiesRisk AssessmentRisk FactorsUnited StatesHypoglycemic Agents

Identifiers

PMID28828479
PMCPMC5624849
OpenAlexW2749343537

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.